PriceTargets.com logo

NASDAQ:TBIO - Translate Bio Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $38.00
  • Forecasted Upside: 1.71 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$37.36 As of 02/28/2022 01:00 AM ET
+0.30 (1.20%)
Get New Translate Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TBIO

Analyst Price Target is $38.00
▲ +1.71% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Translate Bio in the last 3 months. The average price target is $38.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 1.71% upside from the last price of $37.36.

This chart shows the closing price for TBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 4 polled investment analysts is to hold stock in Translate Bio. This rating has held steady since March 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/3/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
6/1/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
8/30/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
11/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
2/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/3/2021Roth CapitalLower Price TargetBuy ➝ Neutral$45.00 ➝ $38.00Low
8/3/2021SVB LeerinkBoost Price TargetMarket Perform$19.00 ➝ $38.00Medium
8/3/2021Jefferies Financial GroupDowngradeBuy ➝ HoldMedium
8/3/2021William BlairDowngradeOutperform ➝ Market PerformHigh
7/26/2021Roth CapitalBoost Price TargetBuy$28.00 ➝ $45.00High
5/10/2021SVB LeerinkBoost Price TargetMarket Perform$18.00 ➝ $19.00High
3/29/2021SVB LeerinkReiterated RatingOutperform ➝ Market Perform$21.00 ➝ $18.00N/A
3/24/2021Truist FinancialReiterated RatingBuy ➝ Hold$20.00Medium
3/24/2021Evercore ISIReiterated RatingOutperform ➝ In-Line$21.00Medium
3/23/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$21.00 ➝ $18.00Medium
3/19/2021William BlairReiterated RatingBuyLow
3/18/2021Roth CapitalLower Price TargetBuy$37.00 ➝ $28.00High
3/18/2021Truist FinancialDowngradeBuy ➝ Hold$40.00 ➝ $20.00High
3/18/2021SVB LeerinkLower Price TargetOutperform$33.00 ➝ $21.00High
3/18/2021HC WainwrightLower Price TargetBuy$32.00 ➝ $28.00High
3/1/2021SVB LeerinkLower Price TargetOutperform$34.00 ➝ $33.00Low
12/22/2020Roth CapitalBoost Price Target$30.00 ➝ $37.00Low
11/9/2020SVB LeerinkBoost Price TargetOutperform$30.00 ➝ $34.00High
10/5/2020The Goldman Sachs GroupInitiated CoverageBuy$19.00High
8/19/2020CitigroupLower Price TargetBuy$35.00 ➝ $34.00Medium
7/7/2020HC WainwrightBoost Price TargetBuy$18.00 ➝ $32.00Low
7/6/2020William BlairInitiated CoverageOutperformMedium
6/26/2020SVB LeerinkBoost Price TargetOutperform$21.00 ➝ $30.00High
6/26/2020SunTrust BanksInitiated CoverageBuy$40.00High
6/25/2020CitigroupBoost Price TargetBuy$17.00 ➝ $35.00High
6/23/2020Jefferies Financial GroupBoost Price TargetBuy$17.00 ➝ $29.00High
6/23/2020Roth CapitalBoost Price TargetBuy$25.00 ➝ $30.00High
9/10/2019CitigroupSet Price TargetBuy$17.00Low
8/1/2019HC WainwrightReiterated RatingBuy$21.00Low
7/22/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$20.00High
6/18/2019Roth CapitalInitiated CoverageBuy ➝ Buy$25.00 ➝ $25.00High
5/13/2019HC WainwrightReiterated RatingBuy$21.00High
4/9/2019HC WainwrightReiterated RatingBuy$21.00Medium
1/4/2019HC WainwrightReiterated RatingBuyHigh
12/24/2018HC WainwrightInitiated CoverageBuy ➝ Buy$21.00Low
11/14/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$24.00 ➝ $25.00High
7/23/2018CitigroupInitiated CoverageBuy$20.00Low
7/23/2018Evercore ISIInitiated CoverageOutperform$25.00Low
7/23/2018SVB LeerinkInitiated CoverageOutperform$24.00Low
(Data available from 5/28/2017 forward)

News Sentiment Rating

0.18 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/29/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/29/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/28/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/28/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Translate Bio logo
Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HemeScreen Panel, and ICE COLD-PCR. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.
Read More

Today's Range

Now: $37.36
Low: $37.36
High: $37.36

50 Day Range

MA: $37.45
Low: $36.89
High: $37.77

52 Week Range

Now: $37.36
Low: $11.91
High: $37.99

Volume

10 shs

Average Volume

1,660,263 shs

Market Capitalization

$2.82 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Frequently Asked Questions

What sell-side analysts currently cover shares of Translate Bio?

The following Wall Street research analysts have issued stock ratings on Translate Bio in the last year: Jefferies Financial Group Inc., Roth Capital, SVB Leerink LLC, William Blair, and Zacks Investment Research.
View the latest analyst ratings for TBIO.

What is the current price target for Translate Bio?

0 Wall Street analysts have set twelve-month price targets for Translate Bio in the last year. Their average twelve-month price target is $38.00, suggesting a possible upside of 1.7%.
View the latest price targets for TBIO.

What is the current consensus analyst rating for Translate Bio?

Translate Bio currently has 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TBIO, but not buy more shares or sell existing shares.
View the latest ratings for TBIO.

How do I contact Translate Bio's investor relations team?

Translate Bio's physical mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company's listed phone number is (203) 787-7888. The official website for Translate Bio is www.translate.bio. Learn More about contacing Translate Bio investor relations.